Development of a Candidate 11C-Labeled Selective Phosphodiesterase 1 Radioligand for Positron Emission Tomography
Jian Rong,Tomoteru Yamasaki,Jiahui Chen,Katsushi Kumata,Chunyu Zhao,Masayuki Fujinaga,Kuan Hu,Wakana Mori,Yiding Zhang,Lin Xie,Ahmad F. Chaudhary,Xin Zhou,Wei Zhang,Yabiao Gao,Kuo Zhang,Jimmy S. Patel,Zhendong Song,Thomas L. Collier,Hongjie Yuan,Chongzhao Ran,Ahmed Haider,Yinlong Li,Ming-Rong Zhang,Steven Liang
DOI: https://doi.org/10.1021/acsomega.4c03214
IF: 4.1
2024-01-01
ACS Omega
Abstract:Phosphodiesterases (PDEs) constitute a superfamily of phosphohydrolytic enzymes that regulate intracellular second messenger signaling by hydrolyzing cyclic adenosine monophosphate and cyclic guanosine monophosphate. Among the 11 subfamilies of PDEs, phosphodiesterase 1 (PDE1) stands out due to its broad implications in central and peripheral pathologies. There are three subtypes of PDE1: PDE1A, PDE1B, and PDE1C. While PDE1A and PDE1C are distributed in both the brain and peripheral organs, PDE1B is predominantly expressed in the brain, rendering it an attractive drug target for neurological and psychological disorders. Despite continuous efforts dedicated to the development of novel PDE1 inhibitors, a suitable PDE1 radioligand for human use is currently lacking. In this study, we present the identification and preclinical evaluation of [C-11]PF-04822163, a selective radioligand candidate for imaging PDE1 with positron emission tomography. PF-04822163 exhibits excellent potency toward PDE1 and demonstrates great target selectivity over other PDEs. Then, PF-04822163 was labeled with carbon-11 (half-life, 20 min) in favorable radiochemical yields (25 +/- 10%, decay-corrected) and high molar activities (106-194 GBq/mu mol). Further, in vitro and in vivo evaluations in rodents suggested that [C-11]PF-04822163 displayed good brain penetration and a rapid washout. Despite these promising performance characteristics of [C-11]PF-04822163, only marginal specific binding was observed in vivo. Further optimization of the scaffold is warranted to obtain favorable pharmacological and ADME properties.